Marinomed Biotech AG announces results for the 2023 financial year and reports progress with Marinosolv and Carragelose assets Revenues for the 2023 financial year at EUR 9.2 million after pandemic-driven record years (2022: EUR 11.3 million) Important progress for Carragelose with new distribution partners and new products as well as Marinosolv  [ … ]

Marinomed Biotech AG: Launch of new allergen-blocking Carragelose product in Austria and market entry in Mexico Launch of new allergen-blocking nasal spray in Austria for the treatment of hay fever complements existing OTC product portfolio Partner M8 Pharmaceuticals launches Carragelose nasal spray for the treatment of viral respiratory infectio [ … ]

 Marinomed Biotech AG announces agreement with European Investment Bank (EIB) to defer repayments of the 2019 venture loan for 18 months Agreement with the EIB provides for a deferral of all capital repayments for 18 months, while interest rates remain unchanged Real estate lenders also agreed to suspend repayments for 18 months Marinomed plans  [ … ]

Marinomed Biotech AG enters new Carragelose distribution partnerships for Gulf region and Eastern Europe Gulf-region specialist GAIA Healthcare FZ LLC obtains license for the marketing of Carragelose nasal sprays Expansion of Carragelose partner network in Eastern Europe with VitaPlus Kft. Korneuburg, Austria, 26 March 2024 – Marinomed Biotech AG [ … ]

Marinomed Biotech AG enters new Carragelose distribution partnerships for Gulf region and Eastern Europe Gulf-region specialist GAIA Healthcare FZ LLC obtains license for the marketing of Carragelose nasal sprays Expansion of Carragelose partner network in Eastern Europe with VitaPlus Kft. Korneuburg, Austria, 26 March 2024 – Marinomed Biotech AG [ … ]

Marinomed Biotech AG: Lucia Ziegler new Head of Investor & Public Relations Korneuburg, Austria, 1 March 2024 – Lucia Ziegler will take over the newly integrated "Investor & Public Relations" department at Marinomed Biotech AG (VSE:MARI) as of the beginning of March 2024. In addition to her previous PR tasks, Lucia Ziegler will also be res [ … ]

 Marinomed Biotech AG announces preliminary revenue for 2023 Preliminary revenues eased as expected to € 9.2 m in 2023 (2022: € 11.3 m) due to reduced Carragelose order volumes caused by sufficient customer stock levels Cash position at € 2.6 m; financial stability secured by cost-conscious cash management and convertible note funding program O [ … ]

Marinomed Biotech AG with important progress for Carragelose in 2024 First patient enrolled in clinical study investigating the moisturizing effectiveness of Carragelose eye drops Clinical data showing the effectiveness of Carragelose in alleviating allergic symptoms in patients with grass pollen allergy published in peer-reviewed International J [ … ]